SS1 Optogenetics vs DREADDS: Pros and Cons of New Techniques for Manipulating on Demand Cell Signals In Vivo

Program: Special Scientific Session
Basic Session
Friday, April 1, 2016: 3:30 PM-4:15 PM
Room 160 (BCEC)
Luis de Lecea, PhD, Stanford University School of Medicine, Stanford, CA and Michael Krashes, PhD, NIDDK/NIH, Bethesda,

Nothing to Disclose: LD, MK

The emergence of chemogenetic (DREADDs) and optogenetic tools has revolutionized understanding of the nervous system in health and disease. While both tools have been applied to the study of neuroscience, metabolism and beyond, it is becoming clear that each has practical advantages for studying specific biological questions. The speakers in this session will discuss their experiences using chemogenetics and optogenetics, and attendees will learn how they can leverage these tools for their research.


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire